News Channels

06 Feb 2019 BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
06 Feb 2019 Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
06 Feb 2019 Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
06 Feb 2019 FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
06 Feb 2019 MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
05 Feb 2019 Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
05 Feb 2019 Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
05 Feb 2019 FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam)
05 Feb 2019 Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers
05 Feb 2019 US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
05 Feb 2019 Genentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
05 Feb 2019 Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
05 Feb 2019 CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
05 Feb 2019 Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
05 Feb 2019 ProteoNic Biotechnology Licenses Protein Production Technology to Eli Lilly and Company
04 Feb 2019 Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A Without Inhibitors
04 Feb 2019 Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant
04 Feb 2019 SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug
04 Feb 2019 Neurana Pharmaceuticals Announces First Patient Enrolled in the "STAR Study," a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back
04 Feb 2019 Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up